# Optimization of Antiretroviral Therapy

> **NCT02935075** · PHASE4 · COMPLETED · sponsor: **Shanghai Public Health Clinical Center** · enrollment: 184 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate
- **DRUG:** Lamivudine
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT02935075
- **Lead sponsor:** Shanghai Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2019-06-05
- **Final completion:** 2019-08-31
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2020-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935075, "Optimization of Antiretroviral Therapy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02935075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*